ES2170760T3 - Inversion del fenotipo de celulas transformadas por el factor de transcripcion irf-1. - Google Patents

Inversion del fenotipo de celulas transformadas por el factor de transcripcion irf-1.

Info

Publication number
ES2170760T3
ES2170760T3 ES94116044T ES94116044T ES2170760T3 ES 2170760 T3 ES2170760 T3 ES 2170760T3 ES 94116044 T ES94116044 T ES 94116044T ES 94116044 T ES94116044 T ES 94116044T ES 2170760 T3 ES2170760 T3 ES 2170760T3
Authority
ES
Spain
Prior art keywords
irf
investment
phenotype
transcription factor
cells transformed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94116044T
Other languages
English (en)
Inventor
Taniguchi Tadatsugu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Application granted granted Critical
Publication of ES2170760T3 publication Critical patent/ES2170760T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Collating Specific Patterns (AREA)
  • Tires In General (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DEL IRF-1 O DE ACIDOS NUCLEICOS QUE CONTIENEN INFORMACION DE CODIFICACION PARA EL IRF-1 PARA LA INVERSION DEL FENOTIPO DE CELULAS TRANSFORMADAS. LOS ACIDOS NUCLEICOS QUE CODIFICAN EL IRF-1 PUEDEN UTILIZARSE COMO GENES SUPRESORES DE TUMORES EN LA TERAPIA DE GENES CONTRA EL CANCER.
ES94116044T 1993-10-19 1994-10-12 Inversion del fenotipo de celulas transformadas por el factor de transcripcion irf-1. Expired - Lifetime ES2170760T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93116854A EP0648493A1 (en) 1993-10-19 1993-10-19 A method to reverse the phenotype of transformed cells by the transcription factor IRF-1

Publications (1)

Publication Number Publication Date
ES2170760T3 true ES2170760T3 (es) 2002-08-16

Family

ID=8213351

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94116044T Expired - Lifetime ES2170760T3 (es) 1993-10-19 1994-10-12 Inversion del fenotipo de celulas transformadas por el factor de transcripcion irf-1.

Country Status (9)

Country Link
US (1) US5658774A (es)
EP (2) EP0648493A1 (es)
JP (1) JP3549266B2 (es)
AT (1) ATE211912T1 (es)
CA (1) CA2118373C (es)
DE (1) DE69429647T2 (es)
DK (1) DK0654268T3 (es)
ES (1) ES2170760T3 (es)
PT (1) PT654268E (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869040A (en) * 1995-06-07 1999-02-09 Biogen, Inc Gene therapy methods and compositions
US20030104356A1 (en) * 1999-11-22 2003-06-05 Smithkline Beecham Corporation Compounds and methods for treating and screening viral reactivation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0355190A1 (en) * 1988-08-24 1990-02-28 Tadatsugu Dr. Taniguchi Factor regulating gene expression
ATE105861T1 (de) * 1988-08-24 1994-06-15 Tadatsugu Taniguchi Gen-expression regulierender faktor.
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
IL103059A0 (en) * 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
MX9305855A (es) * 1992-09-24 1995-01-31 Tadatsugu Taniguchi Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad.

Also Published As

Publication number Publication date
DK0654268T3 (da) 2002-03-11
EP0648493A1 (en) 1995-04-19
DE69429647D1 (de) 2002-02-21
EP0654268A1 (en) 1995-05-24
CA2118373A1 (en) 1995-04-20
JPH07184654A (ja) 1995-07-25
JP3549266B2 (ja) 2004-08-04
EP0654268B1 (en) 2002-01-16
ATE211912T1 (de) 2002-02-15
DE69429647T2 (de) 2002-08-14
PT654268E (pt) 2002-04-29
CA2118373C (en) 2008-09-23
US5658774A (en) 1997-08-19

Similar Documents

Publication Publication Date Title
DE69434486D1 (de) Adenovirus vektoren für gentherapie
AR241314A1 (es) Aislado de adn, vector en base en dicho aislado cultivo de celulas tratadas con dicho vector y preparacion de factor viii humano funcional.
ES2054878T3 (es) Expresion de la proapolipoproteina a-i humana.
WO1993021942A3 (en) Use of mmp inhibitors
FI961976A0 (fi) Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina
AR020209A1 (es) Celulosa sintetasas del maiz y usos de las mismas
ES2107762T3 (es) Utilizacion de un alquilester de glutation en una composicion cosmetica o dermatologica destinada al tratamiento por via topica del envejecimiento cutaneo.
ES2180622T3 (es) Oligonucleotidos antisentido con actividad inhibidora de tumorigenicidad.
ATE224736T1 (de) Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie
ATE404226T1 (de) Zusammensetzung enthaltend auf festen teilchen immobilisierte radioisotopen, sowie deren verwendung in der brachytherapie
ATE485375T1 (de) Nukleinsäuren zum auslösen der tumorzellsterblichkeit
DE3376295D1 (en) Pharmaceutical composition containing adenosine derivatives for use in treating tumours
NO20000784L (no) Nye aggrecanaseinhibitorer og matriksmetalloproteinaser for behandling av artritt
BR0309127A (pt) Composição para proliferação de células
DE60023660D1 (de) Antizymmodulatoren sowie deren verwendung
AR047574A1 (es) Genes del ciclo celular y metodos de uso relacionados
ES2059320T3 (es) Nuevos diarilalcanoides que tienen actividad como inhibidores de lipoxigenasa.
DK1144600T3 (da) Akt-3-nukleinsyre, polypeptider og anvendelser deraf
ES2074280T3 (es) Metodo para modificar el tropismo de celula, tejido o huesped de un microorganismo, microorganismos recombinantes obtenidos de este modo y su uso en medicina y medicina veterinaria.
ES2180666T3 (es) Anfifilos cationicos y plasmidos para suministro intracelular de moleculas terapeuticas.
ES2170760T3 (es) Inversion del fenotipo de celulas transformadas por el factor de transcripcion irf-1.
DE69934987D1 (de) Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen
ES8105279A1 (es) Metodo de estabilizar composiciones acuosas de peroxido de benzoilo
ES2086651T3 (es) Nuevos compuestos, denominados "leustroducsinas", su preparacion y sus utilizaciones terapeuticas.
ATE283921T1 (de) Zell- und/oder tumor-spezifische promotor- abhängige änderung der gezielten expression des herpes gamma 34.5 gens

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 654268

Country of ref document: ES